Cryo-Cell International, Inc.

Total Valuation

Cryo-Cell International, Inc. carries a market capitalization of 27.79M, placing it among publicly traded companies globally. Its enterprise value stands at 52.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Cryo-Cell International, Inc. currently has 8.06M shares outstanding.

Valuation Ratios

Cryo-Cell International, Inc. trades at a trailing price-to-earnings ratio of 504.00. The price-to-sales ratio is 1.29, and the price-to-book ratio stands at -1.17.

Enterprise Valuation

On an enterprise value basis, Cryo-Cell International, Inc. trades at an EV/EBITDA multiple of 10.19 and an EV/FCF ratio of 7.98. The EV/Sales ratio of 1.65 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.81 provides insight into valuation relative to core operating earnings.

Financial Position

Cryo-Cell International, Inc. maintains a current ratio of 0.60, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -101.33, indicating conservative leverage, while an interest coverage ratio of 2.22 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Cryo-Cell International, Inc. has paid 1.82M in income taxes, reflecting an effective tax rate of 110.41.

Stock Price Statistics

Cryo-Cell International, Inc.'s stock has declined approximately -31.68317% over the past 52 weeks. The 50-day moving average sits at 3.51, while the 200-day moving average is 3.84.

Income Statement

Over the trailing twelve months, Cryo-Cell International, Inc. generated 31.99M in revenue and converted that into -171,296.00 in net income, yielding earnings per share of -0.02. EBITDA reached 5.17M, while operating income came in at 3.82M.

Balance Sheet

Cryo-Cell International, Inc. holds 4.43M in cash and equivalents against 15.77M in total debt, resulting in a net debt position of 14.90M. Total book value stands at -35.22M, with working capital of -8.70M providing operational flexibility.

Cash Flow

Cryo-Cell International, Inc. produced 6.26M in operating cash flow over the past twelve months. After subtracting -585,181.00 in capital expenditures, free cash flow totaled 5.67M - equivalent to 0.70 per share.

Margins

Cryo-Cell International, Inc. operates with a gross margin of 76.23, reflecting its pricing power and cost economics. The operating margin of 11.93 and net profit margin of -0.54 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -1,886.34 indicates the proportion of earnings distributed to shareholders.

Scores

Cryo-Cell International, Inc. posts an Altman Z-Score of 0.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.